HRA001346
Title:
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by circulating tumor DNA in resected non-small cell lung cancer
Release date:
2021-09-23
Description:
Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluated the clinical utility of circulating tumor DNA (ctDNA) for dynamic recurrence risk and adjuvant chemotherapy (ACT) benefit prediction in resected non-small cell lung cancer (NSCLC).
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Cohort Study
Disease name:
lung cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Lung cancer MRD
Contact person:
ZHANG XIAN
Email:
xian.zhang@geneseeq.com
Description:
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Individuals & samples
Submitter:   WEI GUO / guowei@cicams.ac.cn
Organization:   National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Submission date:   2021-05-20
Requests:   0